China FDA Proposes Sweeping Action On Drug Approvals, Poor Quality Submissions
This article was originally published in SRA
Executive Summary
The China Food and Drug Administration has proposed a series of drastic actions to reduce the backlog of drug applications and rapidly push forward planned reforms to its regulatory review system.